| 000 | 01168 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515232340.0 | ||
| 264 | 0 | _c20101216 | |
| 008 | 201012s 0 0 ger d | ||
| 022 | _a1563-258X | ||
| 024 | 7 |
_a10.1007/s10354-010-0792-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFasching, Peter | |
| 245 | 0 | 0 |
_a[Seronegative spondylarthritis]. _h[electronic resource] |
| 260 |
_bWiener medizinische Wochenschrift (1946) _cMay 2010 |
||
| 300 |
_a209-10 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiological Products _xtherapeutic use |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aHLA-B27 Antigen _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-1 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aPhysical Therapy Modalities |
| 650 | 0 | 4 |
_aRheumatoid Factor _xblood |
| 650 | 0 | 4 |
_aSpondylarthritis _xblood |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 773 | 0 |
_tWiener medizinische Wochenschrift (1946) _gvol. 160 _gno. 9-10 _gp. 209-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10354-010-0792-3 _zAvailable from publisher's website |
| 999 |
_c19974863 _d19974863 |
||